Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
4
2
2021
medline:
20
5
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
Zero risk of linked HIV transmission in serodiscordant couples when the HIV-infected partner had viral load less than 200 copies/ml ('U status') was found in observational studies. We aimed at estimating the proportion of time in which 'U status' was maintained and identifying factors associated with the risk of losing it. Observational cohort study. We included participants in the ICONA cohort who had reached an established 'U status' (viral load ≤200 copies/ml for >6 months) as of December 2010. The outcome was the number of person-days of follow-up (PDFU) above a viral load greater than 200 copies/ml, relative to the total number of PDFU observed. A logistic regression model was used to identify factors independently associated with the risk of losing 'U status'. Eight thousand, two hundred and forty-one persons living with HIV were included in the analysis who contributed 2 670 888 PDFU. Of these, 1648 (20%) were women, 768 (9%) were people who inject drugs (PWID), and 2066 (25%) were foreign-born. The median of viral load measurements was 9 (IQR: 4-15). Overall, only 3.1% of PDFU were observed when viral load was above 200 copies/ml. The proportion of PDFU with viral load more than 200 copies/ml was higher than average in women (5.3%), unemployed (5.4%), PWID (4.7%), and in people with more than three previous virologic failures (6.3%). These variables were significant predictors of losing 'U status' in the multivariable logistic regression. Our results reinforce the validity of the U=U message in real-world setting. However, we identified subsets of our study population at higher risk of losing the 'U status' for whom additional efforts are needed.
Identifiants
pubmed: 33534204
doi: 10.1097/QAD.0000000000002825
pii: 00002030-202106010-00011
pmc: PMC9904439
doi:
Substances chimiques
Anti-HIV Agents
0
RNA
63231-63-0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1103-1112Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Lee TH, Sakahara N, Fiebig E, Busch MP, O’Brien TR, Herman SA. Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients . J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:427–428.
Pedraza MA, Del Romero J, Roldán F, García S, Ayerbe MC, Noriega AR, Alcamí J. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner . J Acquir Immune Defic Syndr 1999; 21:120–125.
Holmberg SD, Horsburgh CR, Ward JW, Jaffe HW. Biologic Factors in the Sexual Transmission of Human Immunodeficiency Virus . J Infect Dis 1989; 160:116–125.
Saracco A, Musicco M, Nicolosi A, Angarano G, Arici C, Gavazzeni G, et al. Man–to–woman sexual transmission of HIV: longitudinal study of 343 steady partners of infected men . J Acquir Immune Defic Syndr 1993; 6:497–502.
Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients . J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:42–45.
Operskalski EA, Stram DO, Busch MP, Huang W, Harris M, Dietrich SL, et al. Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients . Am J Epidemiol 1997; 146:655–661.
Musicco M, Lazzarin A, Nicolosi A, Gasparini M, Costiglioia P, Arici C, et al. Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission . Arch Intern Med 1994; 154:1971–1976.
Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1 . N Engl J Med 2000; 342:921–929.
Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d’aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle . Bull des Médecins Suisses 2008; 89:165–169.
Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis . AIDS 2009; 23:1397–1404.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy . N Engl J Med 2011; 365:493–505.
Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Van Lunzen J, et al. PARTNER Study Group. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy . JAMA 2016; 316:171–181.
Rodger AJ, Cambiano V, Phillips AN, Bruun T, Raben D, Lundgren J, et al. PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study . Lancet 2019; 393:2428–2438.
Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, et al. Opposites Attract Study Group. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study . Lancet HIV 2018; 5:E438–E447.
Vernazza P. THE STORY OF U=U: SCIENTIFIC UNDERPINNINGS - CROI Conference. Conf Retroviruses Opportunistic Infect 2019 [Internet]. 2019 [cited 2020 May 22]; Available at: https://www.croiconference.org/abstract/story-uu-scientific-underpinnings . [Accessed 10 August 2020]
D’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients . AIDS 2000; 14:499–507.
Marks G, Gardner LI, Rose CE, Zinski A, Moore RD, Holman S, et al. Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care . AIDS 2015; 29:947–954.
Loutfy MR, Sherr L, Sonnenberg-Schwan U, Walmsley SL, Johnson M, d’Arminio Monforte A. Caring for women living with HIV: gaps in the evidence . J Int AIDS Soc 2013; 16:18509.
Soon GG, Min M, Struble KA, Chan-Tack KM, Hammerstrom T, Qi K, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy . AIDS Patient Care STDS 2012; 26:444–453.
Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, et al. Icona Foundation Study Group. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy . BMC Public Health 2018; 18:870.
Saracino A, Lorenzini P, Lo Caputo S, Girardi E, Castelli F, Bonfanti P, et al. ICONA Foundation Study Group. Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort . Clin Microbiol Infect 2016; 22:288.e1–288.e8.
Reyes-Urueña J, Campbell C, Hernando C, Vives N, Folch C, Ferrer L, et al. Differences between migrants and Spanish-born population through the HIV care cascade, Catalonia: an analysis using multiple data sources . Epidemiol Infect 2017; 145:1670–1681.
Weijsenfeld AM, Blokhuis C, Stuiver MM, Wit FWNM, Pajkrt D, Singh S. Longitudinal virological outcomes and factors associated with virological failure in behaviorally HIV-infected young adults on combination antiretroviral treatment in the Netherlands, 2000 to 2015 . Medicine (Baltimore) 2019; 98:e16357.
Weber R, Huber M, Battegay M, Stähelin C, Castro Batanjer E, Calmy A, et al. Swiss HIV Cohort Study. Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study . HIV Med 2015; 16:137–151.
Laut KG, Shepherd L, Gottfredsson M, Sedlacek D, Knysz B, Begovac J, et al. EuroSIDA study group. Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations . AIDS 2018; 32:2807–2819.
Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users . AIDS 2013; 27:2559–2566.
D’Almeida KW, Lert F, Spire B, Dray-Spira R. Determinants of virological response to antiretroviral therapy: Socio-economic status still plays a role in the era of cART. Results from the ANRS-VESPA 2 study, France . Antivir Ther 2016; 21:661–670.
Socio-economic Inequalities and HIV Working Group for Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in Euro-Coord. Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe . AIDS 2017; 31:253–262.
Armenia D, Carlo DDi, Cozzi-Lepri A, Calcagno A, Borghi V, Gori C, et al. Very high pretherapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen . Antivir Ther 2019; 24:321–331.
Eshleman SH, Wilson EA, Zhang XC, Ou SS, Piwowar-Manning E, Eron JJ, et al. Virologic outcomes in early antiretroviral treatment: HPTN 052 . HIV Clin Trials 2017; 18:100–109.
Skowron G, Street JC, Obee EM. Baseline CD4+ cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy . J Acquir Immune Defic Syndr 2001; 28:313–319.
Stirrup OT, Sabin CA, Phillips AN, Williams I, Churchill D, Tostevin A, et al. Associations between baseline characteristics, CD4+ cell count response and virological failure on first-line efavirenz+tenofovir+emtricitabine for HIV . J Virus Erad 2019; 5:204–211.
Rusconi S, Santoro MM, Gianotti N, Antinori A, Bonora S, Cingolani A, et al. Icona Foundation Study Group. Is the rate of virological failure to cART continuing to decline in recent calendar years? . J Clin Virol 2019; 116:23–28.
Reekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, et al. EuroSIDA Study Group. history of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change . HIV Med 2010; 11:469–478.
Calabrese SK, Mayer KH. Providers should discuss U=U with all patients living with HIV . Lancet HIV 2019; 6:e137–e140.